论文部分内容阅读
目的本文针对尿激酶和阿替普酶分别治疗急性脑梗死的疗效以及用药后对患者的安全进行分析讨论。方法选取我科2014年11月至2016年8月溶栓49例急性脑梗死患者,发病2~6小时内,分为两组进行分析。常规组利用尿激酶静脉滴注治疗患者有31例,治疗组患者利用阿替普酶静脉溶栓治疗18例;男性患者21例,女性患者28例~([1])。比较两组患者NIHSS评分、应用药物治疗的效果、颅内与牙龈出血的人数、出院后患者的恢复情况以及死亡人数。结果阿替普酶与尿激酶病例比较尿激酶疗效不低于阿替普酶,死亡皆是大面积梗死和并心律失常,2小时内溶栓、NIHSS评分5~10分的疗效尤佳,所得数据计算使P<0.05,具有统计学意义;男性患者与女性患者的疗效与临床不良反应出现的人数进行数据计算使得P>0.05,不具有统计学意义。结论两组患者治疗过程中,尿激酶疗效及安全性不低于阿替普酶,且与年龄性别无关。
Objective In this paper, urokinase and alteplase for the treatment of acute cerebral infarction and the efficacy of the treatment of patients after the safety analysis. Methods Forty-nine patients with acute cerebral infarction who underwent thrombolysis in our department from November 2014 to August 2016 were selected and divided into two groups for analysis within 2 to 6 hours. In the conventional group, 31 patients were treated with intravenous infusion of urokinase, and 18 patients in the treatment group were treated with intravenous thrombolysis with alteplase. There were 21 male patients and 28 female patients (1). The NIHSS score, the effect of medication, the number of intracranial and gingival bleeding, the recovery from hospital discharge, and the number of deaths were compared between the two groups. Results of alteplase and urokinase cases compared urokinase efficacy is not lower than alteplase, death are large infarcts and arrhythmia, thrombolysis within 2 hours, NIHSS score 5 to 10 is particularly effective in the treatment of Data calculated so that P <0.05, with statistical significance; male patients and female patients efficacy and clinical adverse reactions occurred in the number of data calculated so that P> 0.05, not statistically significant. Conclusion During the course of treatment, the efficacy and safety of urokinase are not lower than that of alteplase, and have no relation with age and sex.